

# **CURRICULUM VITAE FOR CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE**

**MAY 16, 2025**

## **PERSONAL INFORMATION**

Name; last, first middle	Zabor, Emily Craig
Credentials; MD, PhD, etc.	MS, DrPH
Institution / Institute	Cleveland Clinic, Lerner Research Institute
Department	Quantitative Health Sciences
Office Address & Mail Code	9500 Euclid Ave, Cleveland, OH 44195, CA-60
Office Phone	216-387-8625
Office Email	zabore2@ccf.org

## **EDUCATION & TRAINING**

### **Education**

School & City, State / Country	Grinnell College, Grinnell, IA
Degree	BA, Anthropology
Start-End Dates	08/1999 – 05/2003
School & City, State / Country	University of Minnesota, Minneapolis, MN
Degree	MS, Biostatistics
Start-End Dates	08/2008 – 05/2010
School & City, State / Country	Columbia University, New York, NY
Degree	DrPH, Biostatistics
Start-End Dates	01/2013 – 02/2019

### **PhD Thesis**

Title	Statistical Methods for the Study of Etiologic Heterogeneity
Thesis Committee Members	Colin B. Begg, PhD, Shuang Wang, PhD, Yuanjia Wang, PhD, Min Qian, PhD, Mary Beth Terry, PhD

## **PROFESSIONAL APPOINTMENTS**

Position	Associate Staff
Institution / Institute	Cleveland Clinic, Lerner Research Institute
Department	Department of Quantitative Health Sciences
Institution / Institute	Cleveland Clinic, Taussig Cancer Institute
Department	Department of Medical Oncology
Start-End Dates	12/2023 – present
Position	Assistant Staff
Institution / Institute	Cleveland Clinic, Lerner Research Institute
Department	Department of Quantitative Health Sciences
Institution / Institute	Cleveland Clinic, Taussig Cancer Institute
Department	Department of Medical Oncology
Start-End Dates	07/2019 – 12/2023
Position	Senior Research Biostatistician
Institution & Institute	Memorial Sloan Kettering Cancer Center

Department  
City, State / Country  
Start-End Dates

Department of Epidemiology & Biostatistics  
New York, New York, USA  
04/2018 – 06/2019

Position  
Institution & Institute  
Department  
City, State / Country  
Start-End Dates

Research Biostatistician II  
Memorial Sloan Kettering Cancer Center  
Department of Epidemiology & Biostatistics  
New York, New York, USA  
08/2015 – 03/2018

Position  
Institution & Institute  
Department  
City, State / Country  
Start-End Dates

Research Biostatistician  
Memorial Sloan Kettering Cancer Center  
Department of Epidemiology & Biostatistics  
New York, New York, USA  
10/2012 – 07/2015

Position  
Institution & Institute  
Department  
City, State / Country  
Start-End Dates

Assistant Research Biostatistician  
Memorial Sloan Kettering Cancer Center  
Department of Epidemiology & Biostatistics  
New York, New York, USA  
08/2010 – 09/2012

## **ACADEMIC APPOINTMENTS**

Rank, Department  
Institution & City, State / Country  
Start-End Dates

Associate Professor of Medicine  
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA  
01/2025 - present

Rank, Department  
Institution & City, State / Country  
Start-End Dates

Assistant Professor of Medicine  
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA  
03/2020 – 12/2024

Rank, Department  
Institution & City, State / Country  
Start-End Dates

Adjunct Professor  
Hunter College, New York, New York, USA  
09/2016 - 06/2017

## **ADDITIONAL CAREER DEVELOPMENT**

### **Research Development**

School / Institution  
Title / Certificate  
Start-End Dates

The University of Minnesota, Division of Health Policy & Management  
Research Assistant  
2008-2009

School / Institution  
Title / Certificate  
Start-End Dates

National Institutes of Health, Eunice Kennedy Shriver National Institute for Child Health & Human Development  
Summer Intern in Biomedical Research  
2009

School / Institution  
Title / Certificate  
Start-End Dates

The University of Minnesota, Coordinating Centers for Biometric Research  
Research Assistant  
2009-2010

### **Editorial Development**

School / Institution	American Society of Clinical Oncology
Title / Certificate	Editorial Fellowship, Journal of Clinical Oncology
Start-End Dates	July 1, 2022-June 30, 2023

## **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

Name of Society	American Statistical Association
Role / Title	Member
Start-End Dates	2010-present
Name of Society	Eastern North American Region of the International Biometric Society
Role / Title	Member
Start-End Dates	2011-present
Name of Society	American Society of Clinical Oncology
Role / Title	Member
Start-End Dates	2015-2019
Name of Society	Society for Epidemiologic Research
Role / Title	Member
Start-End Dates	2017-2019
Name of Society	Eastern North American Region of the International Biometric Society
Role / Title	Council for Emerging and New Statisticians Committee Member
Start-End Dates	2019-2021
Name of Society	International Society for Clinical Biostatistics
Role / Title	Member
Start-End Dates	2022-present

## **PROFESSIONAL SERVICES**

### **Editorial Board Membership**

Journal 1	Journal of Urology, Editorial Board of Statisticians
Start-End Dates	2018-2020
Journal 2	European Urology, Statistical Associate Editor
Start-End Dates	2019-2021
Journal 3	R Journal, Associate Editor
Start-End Dates	2020-2024
Journal 4	Journal of Urology, Chief Statistician
Start-End Dates	2021-2024
Journal 5	Journal of Clinical Oncology
Start-End Dates	2024-present
Journal 5	R Journal, Executive Editor
Start-End Dates	2025-present

### **Manuscript Reviewer**

Journal 1	Journal of Urology
Start-End Dates	2013-2017

Journal 2  
Start-End Dates

Journal of Clinical Oncology  
2017-2023

Journal 3  
Start-End Dates

Journal of the American Statistical Association  
2018-present

Journal 3  
Start-End Dates

R Journal  
2019-2020

Journal 3  
Start-End Dates

ROpenSci  
2021-present

**Advisory Groups**

Organization  
Title  
Start-End Dates

R-Ladies, NYC  
Board Member  
2016-2019

Organization  
Title  
Start-End Dates

Biodesix, Inc.  
Data and Safety Monitoring Board member  
2023-present

**COMMITTEE SERVICE**

**International**

Organization  
Committee Name / Role  
Start-End Dates

International Society for Clinical Biostatistics  
ISCB44 Scientific Program Committee  
2022-2023

**National**

Organization  
Committee Name / Role  
Start-End Dates

R/Medicine  
R/Medicine Conference Organizing Committee, Member  
2022-2024

Organization  
Committee Name / Role  
Start-End Dates

American Statistical Association  
Statistical Graphics Section, Program-Chair Elect  
2024

Organization  
Committee Name / Role  
Start-End Dates

American Association for Cancer Research/American Society for Clinical  
Oncology  
Methods in Clinical Cancer Research Workshop, Faculty  
2024-present

Organization  
Committee Name / Role  
Start-End Dates

R/Medicine  
R/Medicine Conference Organizing Committee, Chair  
2024-present

Organization  
Committee Name / Role  
Start-End Dates

American Statistical Association  
Statistical Graphics Section, Program Chair  
2025

**Cleveland Clinic**

Committee Name / Role  
Start-End Dates

CCLCM Clinical Research Block Presentations, Faculty Assessor  
2019, 2020, 2022

Committee Name / Role	2 <sup>nd</sup> Annual Advances in Early Lung Cancer Detection Conference Breakout Sessions, Statistician Contributor
Start-End Dates	2019
Committee Name / Role	LRI Staff Biostatistician, Search Committee Member
Start-End Dates	2020
Committee Name / Role	CCF Research Day, Clinical Abstract Review Committee Member
Start-End Dates	2020
Committee Name / Role	Taussig Cancer Institute Hematologic Fellows Journal Club, Statistical Mentor
Start-End Dates	2020-present
Committee Name / Role	Global Center for Pathogen and Human Health Research Young Investigators Award, Grant Review Committee
Start-End Dates	2023
Committee Name / Role	F. Merlin Bumpus Junior Investigator Award, Judge
Start-End Dates	2023
Committee Name / Role	QHS-PM Staff Biostatistician, Search Committee Chair
Start-End Dates	2024, 2025

#### **Memorial Sloan Kettering Cancer Center**

Committee Name / Role	R User Group, Member
Start-End Dates	2016-2019
Committee Name / Role	Coding Workshop, Founder & Chair
Start-End Dates	2018-2019

#### **HONORS & AWARDS**

Mortar Board Honor Society, Grinnell College, 2002-2003

Ralph A. Leubben Prize for Anthropology, Grinnell College, 2003

Outstanding Teaching Assistant Award, The University of Minnesota, 2009

Travel Awardee, American Statistical Association Section on Statistics in Epidemiology, 2017

Award of Merit, The Journal of Urology, 2023

Top 5 Reviewer, Journal of Clinical Oncology, 2023

#### **TEACHING ACTIVITIES**

##### **Curriculum/ Course Development**

1. Introduction to Biostatistics, Hunter College, New York, NY  
Spent 3 hours/week creating content and 3 hours/week teaching the course, 2016-2017 academic year.  
Developed the full curriculum including selecting textbooks, creating course content, designing assignments, writing exams. Graded all assignments and exams. Answered student questions and provided feedback.

##### **Invited Lectures**

##### **International**

1. “Bayesian Basket Trial Design With False Discovery Rate Control.” International Indian Statistical Association Conference, Virtual. 05/2021.
2. “Brief Introduction to Phase II Designs in Oncology.” Seventh International Conference on Statistics for Twenty-first Century, Virtual. 12/2021.
3. “Bayesian Basket Trial Design with False Discovery Rate Control.” 43rd Annual Conference of the International Society for Clinical Biostatistics, Newcastle, United Kingdom. 08/2022.

#### **National**

1. “How Long Will I Live? The Statistics Behind Prognosis In Cancer Research.” New York R Conference, New York, NY. 04/2018.
2. “Teaching Survival Analysis To Clinical Collaborators.” R/Medicine Conference, New Haven, CT. 09/2018.
3. “Statistical Methods For The Study Of Etiologic Heterogeneity.” NYU School of Medicine Department of Population Health, Division of Biostatistics, New York, NY. 10/2018.
4. “Statistical Methods For The Study Of Etiologic Heterogeneity.” Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY. 12/2018.
5. “Reporting Effect Size And Precision In Clinical Research.” American Urological Association Methods in Clinical Urology Research (MCUR) Workshop, Virtual. 07/2021.
6. “Correlating Surrogate Endpoints With Overall Survival At The Individual Patient Level For Precision Oncology.” Joint Statistical Meetings, Virtual. 08/2021.
7. “Optimal Sequential Predictive Probability Designs for Early Phase Expansion Cohorts.” Eastern North American Region of the International Biometric Society Meetings, Houston, TX. 03/2022.
8. “Estimands, interval censoring, and COVID-19-related disruptions to oncology clinical trials.” University of Colorado Biostatistics Seminar Series, Virtual. 04/2022.
9. “Creating publication-ready summary tables with {gtsummary}.” Harvard Data Science Initiative R User Group, Virtual. 12/2022.
10. “Using the case study of Atezolizumab development to rethink early phase oncology trial design.” Dana-Farber Cancer Institute Department of Data Science Frontiers in Biostatistics Seminar Series, Virtual. 02/2023.
11. “Randomized optimal efficiency predictive probability designs for early phase biomarker-targeted oncology trials.” New England Statistics Symposium annual meeting, Boston, MA, 06/2023.
12. “Reporting Survival Analysis Results with the {gtsummary} and {ggsurvfit} Packages.” New York R Conference, New York, NY. 05/2024.
13. “Introduction to Survival Analysis in R.” R-Ladies Philadelphia, Virtual. 12/2024.
14. “A Two-Stage Randomized Dose Optimization Design for Biomarker-Targeted Phase I Oncology Trials.” Western North American Region of the International Biometric Society Meetings, Whistler, BC, Canada. 06/2025.

#### **Regional/Midwest**

1. "Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous." Mayo Clinic Department of Health Sciences Research, Rochester, MN. 09/2018.
2. "Using the case study of Atezolizumab to rethink early phase oncology trial design." University of Michigan Biostatistics Seminar Series, Ann Arbor, MI. 11/2022.

#### **Local**

1. "Statistical Methods For The Study Of Etiologic Heterogeneity." Cleveland Clinic Department of Quantitative Health Sciences, Cleveland, OH. 11/2018.
2. "Creating Presentation-Ready Summary Tables With {gtsummary}." Greater Cleveland R User Group, Cleveland, OH. 09/2020.
3. "Optimal efficiency predictive probability design for early phase oncology clinical trials." Cleveland Clinic, Case Western Reserve University, Ohio State University 2023 Annual Joint Biostatistics Symposium, Cleveland, OH. 04/2023.
4. "Can AI do the trick?" Ohio Ocular Oncology Symposium, Cleveland, OH. 09/2023.
5. "Using the case study of atezolizumab development to rethink early phase oncology trial design." Case Comprehensive Cancer Center Population and Cancer Prevention Seminar Series, Cleveland, OH. 01/2024.
6. "Cancer biostatistics in academic medicine – a perspective on master's and faculty level positions." Case Western Reserve University Department of Biostatistics Student Career Seminar Series, Cleveland, OH. 02/2024.
7. "Machine Learning and AI Methods." Ohio Ocular Oncology Symposium, Cleveland, OH. 06/2025.

#### **Grand Rounds**

##### **National**

1. "Etiologic Heterogeneity In Cancer." Cleveland Clinic Florida Cancer Grand Rounds, Weston, FL. 01/2020.

#### **Other Presentations**

##### **International**

1. "Initial Reactions To Tobacco And Risk Of Future Regular Tobacco Use." Poster presentation, Third North American Congress of Epidemiology, Montreal, Canada. 06/2011.
2. "A Review Of Statistical Methods For Evaluating Etiologic Heterogeneity." Oral presentation, Third International Molecular Pathologic Epidemiology Meeting, Boston, MA. 03/2016.
3. "Variable Selection and Its Applications in Biomedical Sciences." Session chair, International Indian Statistical Association Meeting, Virtual. 05/2021.

##### **National**

1. "Association Between Periodontal Disease, Bacterial Vaginosis, And Sexual Risk Behaviours." Oral presentation, American Association for Dental Research Meetings, Washington DC. 03/2010.
2. "A Comparison Of Statistical Methods For The Study Of Etiologic Heterogeneity." Poster presentation, Eastern North American Region of the International Biometric Society, Washington DC. 03/2017.
3. "A Comparison Of Statistical Methods For The Study Of Etiologic Heterogeneity." Poster presentation, Society for Epidemiologic Research, Seattle, WA. 06/2017.

4. “Dimension Reduction In The Study Of Etiologic Heterogeneity.” Oral presentation, Joint Statistical Meetings, Baltimore, MD. 09/2017.
5. “Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous.” Oral presentation, Eastern North American Region of the International Biometric Society, Atlanta, GA. 03/2018.
6. “Validity Of A Method For Identifying Disease Subtypes That Are Etiologically Heterogeneous.” Oral/poster presentation, Joint Statistical Meetings, Vancouver, Canada. 07/ 2018.
7. “Trial Design with Subpopulation Heterogeneity: What Is the Role of Real-World Evidence?” Session chair, Joint Statistical Meetings, Virtual. 08/2020.
8. “Designing Early Phase Clinical Trials With {ppseq}.” R/Medicine Conference, Virtual. 08/2021.
9. “Reporting survival analysis results with the {gtsummary} and {ggsurvfit} packages.” R/Medicine Conference, Virtual. 06/2024.

#### **Trainees/Mentees**

1. Sneha Govande, PhD; Postdoctoral Researcher, Cleveland Clinic, 05/2023-05/2025.
2. Millennia Zhou, BS; Internship/Practicum, Case Western Reserve University MS Biostatistics, 09/2023-11/2023.
3. Yohanna Bedelu; Grinnell College Undergraduate Summer Internship, 06/2024-08/2024.
4. Kamilla Abdurakhmanov, BS; Internship/Practicum, Case Western Reserve University MS Biostatistics, 02/2025-04/2025.

#### **Teaching Activities**

1. Teaching Assistant, Introduction to Biostatistics, 10 hours/week. Graduate students of The University of Minnesota, Minneapolis, MN, 2008-2010.
2. Teaching Assistant, Advanced Topics in Clinical Trials, 10 hours/week. Graduate students of The University of Minnesota, Minneapolis, MN, 2008-2010.
3. Teaching Assistant, Data Science I, 10 hours/week. Graduate students of Columbia University, New York, NY, 2017.
4. “Binary Recursive Partitioning With {rpart} and {rpart.plot}.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 08/2011.
5. “Conditional Survival.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 11/2012.
6. “Longitudinal Data Analysis.” Masters Seminar Series, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 07/2015.
7. “Demonstration of Utility Functions for R Markdown Reports in Word.” R User Group, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 12/2016.
8. “Creating Websites in R.”

R User Group, Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 1 hour tutorial, 01/2018.

R-Ladies NYC Meeting, 1 hour tutorial, 02/2018.



Produced a public-facing website with resulting content at [https://www.emilyzabor.com/tutorials/rmarkdown\\_websites\\_tutorial.html](https://www.emilyzabor.com/tutorials/rmarkdown_websites_tutorial.html).

9. "Survival Analysis in R." R Presenter Series, Memorial Sloan Kettering Cancer Center Department of Strategy & Innovation, New York, NY, 1 hour tutorial, 08/2018.
10. "Introduction to Survival Analysis," two 3-hour lectures. Masters-level biostatisticians of Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics, New York, NY, 03/2019.  
Produced a public-facing website with the resulting content at <https://www.emilyzabor.com/survival-analysis-in-r.html>. This material has been widely used and shared for training purposes internally, nationally, and internationally. 2 hours/quarter maintaining and updating.
11. Co-Instructor, Biostatistics and Epidemiology, two 2-hour lectures. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 05/2021, 05/2022, 05/2023, 05/2024, 05/2025.
12. Faculty Methodologist, Clinical Research Methods Journal Club, 2 hour session. Cleveland Clinic Lerner College of Medicine students, 07/2021, 07/2022.
13. Guest lecturer, Tools course, "Introduction to R and RStudio," 3 hour lecture. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 07/2021, 08/2022, 08/2023.
14. Faculty Instructor, "A Good Read: Demystifying Medical Publishing for Urologists: Insights and Tips From the Editors of The Journal of Urology® and European Urology," 2 hour instructional course. Attendees of the 2024 American Urological Association Annual Meeting. San Antonio, TX, 05/2024.
15. Guest lecturer, Tools course, "Introduction to R and RStudio," five one-hour lectures. PhD students of Cleveland Clinic Lerner College of Medicine Molecular Medicine program, 07/2024.  
Developed original course material specific to the needs of basic science PhD students, and produced a public-facing website to host the materials at <https://www.emilyzabor.com/mmedr/>. 20 hours to develop; 4 hours/year to update and maintain.

## **RESEARCH / GRANT SUPPORT**

### **Active**

Sponsor Agency and ID #	National Institutes of Health/National Cancer Institute (award # 1R37CA300540-01)
Title	Assessing feasibility of gastric cancer screening in the US
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Michelle Kim)
Percent Effort	4%
Percent Salary Support	4%
Total Direct Costs Awarded	\$2,048,207
Start-End Dates	04/01/2025-03/31/2030
Sponsor Agency and ID #	American Cancer Society (award # RSG-24-1322538-01-IBCD)
Title	Intratumoral bacteria modulation of the tumor immune microenvironment in head and neck cancer
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Natalie Silver)
Percent Effort	2%
Percent Salary Support	2%
Total Direct Costs Awarded	\$860,000 (Total awarded amount including indirects - \$946,000)
Start-End Dates	01/2025-12/2028

### **Completed**

Sponsor Agency and ID #	Cleveland Clinic Lerner Research Institute
-------------------------	--

Title	Career Development Award
Total Direct Costs Awarded	\$5000
Start-End Dates	10/2022
Sponsor Agency and ID #	National Cancer Institute
Title	SPORE in Bladder Cancer
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Dean Bajorin)
Percent Effort	25%
Percent Salary Support	25%
Total Direct Costs Awarded	\$2,299,837
Start-End Dates	08/2018-07/2019
Sponsor Agency and ID #	National Heart, Lung, and Blood Institute
Title	Investigation of the Effects of Electronic Cigarettes on Vascular Health
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Helena Furberg)
Percent Effort	5%
Percent Salary Support	5%
Total Direct Costs Awarded	\$128,550
Start-End Dates	09/2016-08/2018
Sponsor Agency and ID #	Chanel Endowment to Fund Survivorship
Title	Body composition and the obesity paradox in renal cell carcinoma
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Helena Furberg)
Percent Effort	3%
Percent Salary Support	3%
Total Direct Costs Awarded	\$25,941
Start-End Dates	01/2016-06/2019
Sponsor Agency and ID #	MSK Chanel Survivorship Research Grant
Title	Body composition and the obesity paradox in renal cell carcinoma
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Helena Furberg)
Percent Effort	3%
Percent Salary Support	3%
Total Direct Costs Awarded	\$48,535
Start-End Dates	01/2016-12/2017
Sponsor Agency and ID #	National Cancer Institute
Title	Do cardiovascular risk factors modify the cardiotoxicity of lymphoma treatments?
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Talya Salz)
Percent Effort	12.5%
Percent Salary Support	12.5%
Total Direct Costs Awarded	\$50,000
Start-End Dates	06/2015-05/2018
Sponsor Agency and ID #	American Cancer Society
Title	Predictors of Post-diagnosis Smoking in Bladder Cancer
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Helena Furberg)
Percent Effort	5%
Percent Salary Support	0%
Total Direct Costs Awarded	\$156,640
Start-End Dates	01/2015-12/2019
Sponsor Agency and ID #	Memorial Sloan Kettering Cancer Center Translational Kidney Cancer Research
Title	Immunohistochemical study of estrogen receptor protein expression in

	ccRCC
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Helena Furberg)
Percent Effort	9%
Percent Salary Support	9%
Total Direct Costs Awarded	\$50,000
Start-End Dates	06/2014-11/2015
Sponsor Agency and ID #	National Cancer Institute
Title	Statistical strategies for Establishing Etiologic Heterogeneity of Tumors
Your Role (PI, Co-PI, Co-Investigator, etc.)	Co-Investigator (PI: Dr. Colin Begg)
Percent Effort	40%
Percent Salary Support	40%
Total Direct Costs Awarded	\$207,500
Start-End Dates	07/2012-05/2018

## **BIBLIOGRAPHY**

### **Peer Reviewed Articles**

1. **Zabor, E. C.**, Klebanoff, M., Yu, K., Zhang, J., Nansel, T., Andrews, W., Schwebke, J., & Jeffcoat, M. (2010). Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours. *J Clin Periodontol*, 37(10), 888-893. doi:10.1111/j.1600-051X.2010.01593.x
2. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., **Zabor, E. C.**, Brogi, E., & Joyce, J. A. (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev*, 25(23), 2465-2479. doi:10.1101/gad.180331.111
3. Brader, P., Abramson, S. J., Price, A. P., Ishill, N. M., Emily, Z. C., Moskowitz, C. S., La Quaglia, M. P., & Ginsberg, M. S. (2011). Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? *J Pediatr Surg*, 46(4), 729-735. doi:10.1016/j.jpedsurg.2010.11.027
4. Moskowitz, C. S., **Zabor, E. C.**, & Jochelson, M. (2012). Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. *Breast J*, 18(6), 557-563. doi:10.1111/tbj.12009
5. Kadota, K., Colovos, C., Suzuki, K., Rizk, N. P., Dunphy, M. P., **Zabor, E. C.**, Sima, C. S., Yoshizawa, A., Travis, W. D., Rusch, V. W., & Adusumilli, P. S. (2012). FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol*, 19(11), 3598-3605. doi:10.1245/s10434-012-2414-3
6. Kadota, K., Suzuki, K., Kachala, S. S., **Zabor, E. C.**, Sima, C. S., Moreira, A. L., Yoshizawa, A., Riely, G. J., Rusch, V. W., Adusumilli, P. S., & Travis, W. D. (2012). A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol*, 25(8), 1117-1127. doi:10.1038/modpathol.2012.58
7. Begg, C. B., & **Zabor, E. C.** (2012). Detecting and exploiting etiologic heterogeneity in epidemiologic studies. *Am J Epidemiol*, 176(6), 512-518. doi:10.1093/aje/kws128
8. Abramson, D. H., Marr, B. P., Dunkel, I. J., Brodie, S., **Zabor, E. C.**, Driscoll, S. J., & Gobin, Y. P. (2012). Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. *Br J Ophthalmol*, 96(4), 499-502. doi:10.1136/bjophthalmol-2011-300498
9. **Zabor, E. C.**, Gonen, M., Chapman, P. B., & Panageas, K. S. (2013). Dynamic prognostication using conditional survival estimates. *Cancer*, 119(20), 3589-3592. doi:10.1002/cncr.28273
10. **Zabor, E. C.**, Li, Y., Thornton, L. M., Shuman, M. R., Bulik, C. M., Lichtenstein, P., Pedersen, N. L., Sullivan, P. F., & Furberg, H. (2013). Initial reactions to tobacco use and risk of future regular use. *Nicotine Tob Res*, 15(2), 509-517. doi:10.1093/ntr/nts180
11. Weiss, M. J., Ito, H., Araujo, R. L., **Zabor, E. C.**, Gonen, M., D'Angelica, M. I., Allen, P. J., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2013). Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. *Ann Surg Oncol*, 20(1), 285-294. doi:10.1245/s10434-012-2583-0
12. Rink, M., **Zabor, E. C.**, Furberg, H., Xylinas, E., Ehdaie, B., Novara, G., Babjuk, M., Pycha, A., Lotan, Y., Trinh, Q. D., Chun, F. K., Lee, R. K., Karakiewicz, P. I., Fisch, M., Robinson, B. D., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on outcomes in bladder cancer patients

- treated with radical cystectomy. *Eur Urol*, 64(3), 456-464. doi:10.1016/j.eururo.2012.11.039
13. Rink, M., Furberg, H., **Zabor, E. C.**, Xylinas, E., Babjuk, M., Pycha, A., Lotan, Y., Karakiewicz, P. I., Novara, G., Robinson, B. D., Montorsi, F., Chun, F. K., Scherr, D. S., & Shariat, S. F. (2013). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*, 63(4), 724-732. doi:10.1016/j.eururo.2012.08.025
  14. Ridge, C. A., Huang, J., Cardoza, S., **Zabor, E. C.**, Moskowitz, C. S., Zakowski, M. F., & Ginsberg, M. S. (2013). Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. *AJR Am J Roentgenol*, 201(5), 959-963. doi:10.2214/ajr.12.10033
  15. Pannu, H. K., Ma, W., **Zabor, E. C.**, Moskowitz, C. S., Barakat, R. R., & Hricak, H. (2013). Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. *ISRN Obstet Gynecol*, 2013, 979345. doi:10.1155/2013/979345
  16. McErlean, A., Panicek, D. M., **Zabor, E. C.**, Moskowitz, C. S., Bitar, R., Motzer, R. J., Hricak, H., & Ginsberg, M. S. (2013). Intra- and interobserver variability in CT measurements in oncology. *Radiology*, 269(2), 451-459. doi:10.1148/radiol.13122665
  17. McErlean, A., Huang, J., **Zabor, E. C.**, Moskowitz, C. S., & Ginsberg, M. S. (2013). Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography. *J Thorac Oncol*, 8(7), 967-973. doi:10.1097/JTO.0b013e3182904bc2
  18. Lefkowitz, R. A., Landa, J., Hwang, S., **Zabor, E. C.**, Moskowitz, C. S., Agaram, N. P., & Panicek, D. M. (2013). Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging. *Skeletal Radiol*, 42(6), 809-818. doi:10.1007/s00256-012-1563-6
  19. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., **Zabor, E. C.**, Janakiraman, M., Garcia-Grossman, I. R., Heguy, A., Viale, A., Bochner, B. H., Reuter, V. E., Bajorin, D. F., Milowsky, M. I., Taylor, B. S., & Solit, D. B. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J Clin Oncol*, 31(25), 3133-3140. doi:10.1200/jco.2012.46.5740
  20. Hakimi, A. A., Furberg, H., **Zabor, E. C.**, Jacobsen, A., Schultz, N., Ciriello, G., Mikkilineni, N., Fiegoli, B., Kim, P. H., Voss, M. H., Shen, H., Laird, P. W., Sander, C., Reuter, V. E., Motzer, R. J., Hsieh, J. J., & Russo, P. (2013). An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J Natl Cancer Inst*, 105(24), 1862-1870. doi:10.1093/jnci/djt310
  21. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Ostroff, J. S., Shariat, S. F., Bochner, B. H., Coleman, J. A., & Dalbagni, G. (2013). Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*, 111(4), 589-595. doi:10.1111/j.1464-410X.2012.11260.x
  22. Begg, C. B., **Zabor, E. C.**, Bernstein, J. L., Bernstein, L., Press, M. F., & Seshan, V. E. (2013). A conceptual and methodological framework for investigating etiologic heterogeneity. *Stat Med*, 32(29), 5039-5052. doi:10.1002/sim.5902
  23. Sfakianos, J. P., Hakimi, A. A., Kim, P. H., **Zabor, E. C.**, Mano, R., Bernstein, M., Karellas, M., & Russo, P. (2014). Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. *Eur J Surg Oncol*, 40(12), 1700-1705. doi:10.1016/j.ejso.2014.04.010
  24. Mano, R., Hakimi, A. A., **Zabor, E. C.**, Bury, M. A., Donati, O. F., Karlo, C. A., Bazzi, W. M., Furberg, H., & Russo, P. (2014). Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. *Can Urol Assoc J*, 8(9-10), E675-680. doi:10.5489/cuaj.1979
  25. Lubetkin, E. I., **Zabor, E. C.**, Brennessel, D., Kemeny, M. M., & Hay, J. L. (2014). Beyond demographics: differences in patient activation across new immigrant, diverse language subgroups. *J Community Health*, 39(1), 40-49. doi:10.1007/s10900-013-9738-1
  26. Hayes, S. A., Soff, G. A., **Zabor, E. C.**, Moskowitz, C. S., Liu, C. C., & Ginsberg, M. S. (2014). Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. *Clin Imaging*, 38(5), 637-640. doi:10.1016/j.clinimag.2014.04.015
  27. Ehdaie, B., Furberg, H., **Zabor, E. C.**, Hakimi, A. A., & Russo, P. (2014). Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. *J Urol*, 191(3), 597-602. doi:10.1016/j.juro.2013.08.081
  28. Do, R. K., Katz, S. S., Gollub, M. J., Li, J., LaFemina, J., **Zabor, E. C.**, Moskowitz, C. S., Klimstra, D. S., & Allen, P. J. (2014). Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. *AJR Am J Roentgenol*, 203(5), 973-979. doi:10.2214/ajr.13.11490

29. Begg, C. B., Seshan, V. E., **Zabor, E. C.**, Furberg, H., Arora, A., Shen, R., Maranchie, J. K., Nielsen, M. E., Rathmell, W. K., Signoretti, S., Tamboli, P., Karam, J. A., Choueiri, T. K., Hakimi, A. A., & Hsieh, J. J. (2014). Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*, 14, 138. doi:10.1186/1471-2288-14-138
30. Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., **Zabor, E. C.**, Shah, R. H., Ren, Q., Bagrodia, A., Kim, P. H., Hakimi, A. A., Ostrovnaya, I., Ramirez, R., Hanrahan, A. J., Desai, N. B., Sun, A., Pinciroli, P., Rosenberg, J. E., Dalbagni, G., Schultz, N., Bajorin, D. F., Reuter, V. E., Berger, M. F., Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., & Coleman, J. A. (2015). Genomic Characterization of Upper Tract Urothelial Carcinoma. *Eur Urol*, 68(6), 970-977. doi:10.1016/j.eururo.2015.07.039
31. Lubetkin, E. I., **Zabor, E. C.**, Isaac, K., Brennessel, D., Kemeny, M. M., & Hay, J. L. (2015). Health literacy, information seeking, and trust in information in Haitians. *Am J Health Behav*, 39(3), 441-450. doi:10.5993/ajhb.39.3.16
32. Kim, P. H., Cha, E. K., Sfakianos, J. P., Iyer, G., **Zabor, E. C.**, Scott, S. N., Ostrovnaya, I., Ramirez, R., Sun, A., Shah, R., Yee, A. M., Reuter, V. E., Bajorin, D. F., Rosenberg, J. E., Schultz, N., Berger, M. F., Al-Ahmadie, H. A., Solit, D. B., & Bochner, B. H. (2015). Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. *Eur Urol*, 67(2), 198-201. doi:10.1016/j.eururo.2014.06.050
33. Begg, C. B., Orlow, I., **Zabor, E. C.**, Arora, A., Sharma, A., Seshan, V. E., & Bernstein, J. L. (2015). Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. *Cancer Med*, 4(9), 1432-1439. doi:10.1002/cam4.456
34. Bambury, R. M., Benjamin, D. J., Chaim, J. L., **Zabor, E. C.**, Sullivan, J., Garcia-Grossman, I. R., Regazzi, A. M., Ostrovnaya, I., Apollo, A., Xiao, H., Voss, M. H., Iyer, G., Bajorin, D. F., & Rosenberg, J. E. (2015). The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. *Oncologist*, 20(5), 508-515. doi:10.1634/theoncologist.2014-0354
35. **Zabor, E. C.**, Furberg, H., Mashni, J., Lee, B., Jaimes, E. A., & Russo, P. (2016). Factors Associated with Recovery of Renal Function following Radical Nephrectomy for Kidney Neoplasms. *Clin J Am Soc Nephrol*, 11(1), 101-107. doi:10.2215/cjn.04070415
36. **Zabor, E. C.**, Heller, G., Schwartz, L. H., & Chapman, P. B. (2016). Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. *Clin Cancer Res*, 22(6), 1341-1347. doi:10.1158/1078-0432.Ccr-15-1441
37. Yu, A. F., Raikhelkar, J., **Zabor, E. C.**, Tonorezos, E. S., Moskowicz, C. S., Adsuar, R., Mara, E., Huie, K., Oeffinger, K. C., Steingart, R. M., & Liu, J. E. (2016). Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. *Biomed Res Int*, 2016, 9363951. doi:10.1155/2016/9363951
38. Tully, C. M., Apolo, A. B., **Zabor, E. C.**, Regazzi, A. M., Ostrovnaya, I., Furberg, H. F., Rosenberg, J. E., & Bajorin, D. F. (2016). The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. *Cancer*, 122(5), 712-721. doi:10.1002/cncr.29801
39. Thong, A. E., Petruzella, S., Orlow, I., **Zabor, E. C.**, Ehdaie, B., Ostroff, J. S., Bochner, B. H., & Furberg Barnes, H. (2016). Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. *Eur Urol Focus*, 2(4), 441-444. doi:10.1016/j.euf.2015.12.002
40. Spitzer, B., Perales, M. A., Kernan, N. A., Prockop, S. E., **Zabor, E. C.**, Webb, N., Castro-Malaspina, H., Papadopoulos, E. B., Young, J. W., Scaradavou, A., Kobos, R., Giralt, S. A., O'Reilly, R. J., & Boulad, F. (2016). Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. *Biol Blood Marrow Transplant*, 22(8), 1449-1454. doi:10.1016/j.bbmt.2016.05.001
41. Murray, K. S., **Zabor, E. C.**, Spaliviero, M., Russo, P., Bazzi, W. M., Musser, J. E., Ari Hakimi, A., Bernstein, M. L., Dalbagni, G., Coleman, J. A., & Furberg, H. (2016). Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. *World J Urol*, 34(12), 1667-1672. doi:10.1007/s00345-016-1832-4
42. Hay, J. L., **Zabor, E. C.**, Kumar, J., Brennessel, D., Kemeny, M. M., & Lubetkin, E. I. (2016). Cancer beliefs and patient activation in a diverse, multilingual primary care sample. *Psychooncology*, 25(9), 1071-1078. doi:10.1002/pon.4196

43. Desai, N. B., Scott, S. N., **Zabor, E. C.**, Cha, E. K., Hreiki, J., Sfakianos, J. P., Ramirez, R., Bagrodia, A., Rosenberg, J. E., Bajorin, D. F., Berger, M. F., Bochner, B. H., Zelefsky, M. J., Kollmeier, M. A., Ostrovnaya, I., Al-Ahmadie, H. A., Solit, D. B., & Iyer, G. (2016). Genomic characterization of response to chemoradiation in urothelial bladder cancer. *Cancer*, 122(23), 3715-3723. doi:10.1002/cncr.30219
44. Dahi, P. B., Morawa, E., Perales, M. A., **Zabor, E. C.**, Devlin, S. M., Maloy, M., Castro-Malaspina, H., O'Reilly, R. J., Papadopoulos, E. B., Jakubowski, A. A., & Giral, S. A. (2016). Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. *Bone Marrow Transplant*, 51(7), 991-993. doi:10.1038/bmt.2016.23
45. Bagrodia, A., Lee, B. H., Lee, W., Cha, E. K., Sfakianos, J. P., Iyer, G., Pietzak, E. J., Gao, S. P., **Zabor, E. C.**, Ostrovnaya, I., Kaffenberger, S. D., Syed, A., Arcila, M. E., Chaganti, R. S., Kundra, R., Eng, J., Hreiki, J., Vacic, V., Arora, K., Oschwald, D. M., Berger, M. F., Bajorin, D. F., Bains, M. S., Schultz, N., Reuter, V. E., Sheinfeld, J., Bosl, G. J., Al-Ahmadie, H. A., Solit, D. B., & Feldman, D. R. (2016). Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. *J Clin Oncol*, 34(33), 4000-4007. doi:10.1200/jco.2016.68.7798
46. Bagrodia, A., Cha, E. K., Sfakianos, J. P., **Zabor, E. C.**, Bochner, B. H., Al-Ahmadie, H. A., Solit, D. B., Coleman, J. A., Iyer, G., Scott, S. N., Shah, R., Ostrovnaya, I., Lee, B., Desai, N. B., Ren, Q., Rosenberg, J. E., Dalbagni, G., Bajorin, D. F., Reuter, V. E., & Berger, M. F. (2016). Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. *J Urol*, 195(6), 1684-1689. doi:10.1016/j.juro.2016.01.006
47. Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., Lee, J. L., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, S., Wood, L. A., Vaishamayan, U. N., Rha, S. Y., Agarwal, N., Yuasa, T., Pal, S. K., Bamias, A., **Zabor, E. C.**, Skanderup, A. J., Furberg, H., Fay, A. P., de Velasco, G., Preston, M. A., Wilson, K. M., Cho, E., McDermott, D. F., Signoretti, S., Heng, D. Y. C., & Choueiri, T. K. (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*, 34(30), 3655-3663. doi:10.1200/jco.2016.66.7311
48. Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E. J., Gao, S. P., Ramirez, R., Cha, E. K., Desai, N. B., **Zabor, E. C.**, Ostrovnaya, I., Gopalan, A., Chen, Y. B., Fine, S. W., Tickoo, S. K., Gandhi, A., Hreiki, J., Viale, A., Arcila, M. E., Dalbagni, G., Rosenberg, J. E., Bochner, B. H., Bajorin, D. F., Berger, M. F., Reuter, V. E., Taylor, B. S., & Solit, D. B. (2016). Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nat Genet*, 48(4), 356-358. doi:10.1038/ng.3503
49. **Zabor, E. C.**, & Begg, C. B. (2017). A comparison of statistical methods for the study of etiologic heterogeneity. *Stat Med*, 36(25), 4050-4060. doi:10.1002/sim.7405
50. Weber, J. J., Jochelson, M. S., Eaton, A., **Zabor, E. C.**, Barrio, A. V., Gemignani, M. L., Pilewskie, M., Van Zee, K. J., Morrow, M., & El-Tamer, M. (2017). MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. *J Am Coll Surg*, 225(6), 740-746. doi:10.1016/j.jamcollsurg.2017.08.027
51. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovnaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. *Clin Cancer Res*, 23(14), 3610-3618. doi:10.1158/1078-0432.Ccr-16-2520
52. Schwitzer, E., Orlov, I., **Zabor, E. C.**, Begg, C. B., Berwick, M., Thomas, N. E., Kanetsky, P. A., & Jones, L. W. (2017). No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. *Pigment Cell Melanoma Res*, 30(4), 424-427. doi:10.1111/pcmr.12594
53. Salz, T., **Zabor, E. C.**, de Nully Brown, P., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., Steingart, R., Vickers, A. J., Svenssen Munksgaard, P., Oeffinger, K. C., & Johansen, C. (2017). Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. *J Clin Oncol*, 35(34), 3837-3843. doi:10.1200/jco.2017.72.4211
54. Pilewskie, M., **Zabor, E. C.**, Mamtani, A., Barrio, A. V., Stempel, M., & Morrow, M. (2017). The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. *Ann Surg Oncol*, 24(12), 3527-3533. doi:10.1245/s10434-017-6016-y
55. McCartan, D. P., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & El-Tamer, M. B. (2017). Oncologic

- Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). *Ann Surg Oncol*, 24(11), 3141-3147. doi:10.1245/s10434-017-5965-5
56. Mauguen, A., **Zabor, E. C.**, Thomas, N. E., Berwick, M., Seshan, V. E., & Begg, C. B. (2017). Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. *J Am Stat Assoc*, 112(517), 54-63. doi:10.1080/01621459.2016.1191499
  57. Manley, B. J., **Zabor, E. C.**, Casuscelli, J., Tennenbaum, D. M., Redzematovic, A., Becerra, M. F., Benfante, N., Sato, Y., Morikawa, T., Kume, H., Fukayama, M., Homma, Y., Ogawa, S., Arcila, M. E., Voss, M. H., Feldman, D. R., Coleman, J. A., Reuter, V. E., Motzer, R. J., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2017). Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. *Eur Urol Focus*, 3(4-5), 421-427. doi:10.1016/j.euf.2016.06.015
  58. Gilbert, E., **Zabor, E. C.**, Stempel, M., Mangino, D., Heerdt, A., & Pilewskie, M. (2017). Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance. *Ann Surg Oncol*, 24(10), 3048-3054. doi:10.1245/s10434-017-5976-2
  59. Gentile, L. F., Plitas, G., **Zabor, E. C.**, Stempel, M., Morrow, M., & Barrio, A. V. (2017). Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. *Ann Surg Oncol*, 24(13), 3896-3902. doi:10.1245/s10434-017-6085-y
  60. Francis, J. H., Brodie, S. E., Marr, B., **Zabor, E. C.**, Mondesire-Crump, I., & Abramson, D. H. (2017). Efficacy and Toxicity of Intravitreal Chemotherapy for Retinoblastoma: Four-Year Experience. *Ophthalmology*, 124(4), 488-495. doi:10.1016/j.ophtha.2016.12.015
  61. Cho, G. Y., Gennaro, L., Sutton, E. J., **Zabor, E. C.**, Zhang, Z., Giri, D., Moy, L., Sodickson, D. K., Morris, E. A., Sigmund, E. E., & Thakur, S. B. (2017). Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. *Eur J Radiol Open*, 4, 101-107. doi:10.1016/j.ejro.2017.07.002
  62. Casuscelli, J., Weinhold, N., Gundem, G., Wang, L., **Zabor, E. C.**, Drill, E., Wang, P. I., Nanjangud, G. J., Redzematovic, A., Nargund, A. M., Manley, B. J., Arcila, M. E., Donin, N. M., Cheville, J. C., Thompson, R. H., Pantuck, A. J., Russo, P., Cheng, E. H., Lee, W., Tickoo, S. K., Ostrovnaya, I., Creighton, C. J., Papaemmanuil, E., Seshan, V. E., Hakimi, A. A., & Hsieh, J. J. (2017). Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. *JCI Insight*, 2(12). doi:10.1172/jci.insight.92688
  63. Boursiquot, B. C., **Zabor, E. C.**, Glezerman, I. G., & Jaimes, E. A. (2017). Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function. *Hypertension*. doi:10.1161/hypertensionaha.117.09275
  64. Begg, C. B., Rice, M. S., **Zabor, E. C.**, & Tworoger, S. S. (2017). Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. *Br J Cancer*, 116(8), 1088-1091. doi:10.1038/bjc.2017.73
  65. Alane, S. R., Shah, S., **Zabor, E. C.**, Vijai, J., Ostrovnaya, I., Garcia-Grossman, I. R., Pendse, D. V., Littman, J., Regazzi, A. M., Offit, K., & Bajorin, D. F. (2017). Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder. *Int J Clin Pharmacol Ther*, 55(3), 203-209. doi:10.5414/cp202856
  66. **Zabor, E. C.**, Coit, D., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018). Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. *Ann Surg Oncol*, 25(8), 2172-2177. doi:10.1245/s10434-018-6370-4
  67. **Zabor, E. C.**, Furberg, H., Lee, B., Campbell, S., Lane, B. R., Thompson, R. H., Antonio, E. C., Noyes, S. L., Zaid, H., Jaimes, E. A., & Russo, P. (2018). Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. *J Urol*, 199(4), 921-926. doi:10.1016/j.juro.2017.10.027
  68. Winer, A. G., **Zabor, E. C.**, Vacchio, M. J., Hakimi, A. A., Russo, P., Coleman, J. A., & Jaimes, E. A. (2018). The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. *Clin Genitourin Cancer*, 16(3), 191-196. doi:10.1016/j.clgc.2017.11.006
  69. Silk, M. T., Mikkilineni, N., Silk, T. C., **Zabor, E. C.**, Ostrovnaya, I., Hakimi, A. A., Hsieh, J. J., Ziv, E., Rekhtman, N., Solomon, S. B., & Durack, J. C. (2018). Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. *Anal Cell Pathol (Amst)*, 2018, 2898962. doi:10.1155/2018/2898962
  70. Scott, J. M., **Zabor, E. C.**, Schwitzer, E., Koelwyn, G. J., Adams, S. C., Nilsen, T. S., Moskowitz, C. S., Matsoukas, K., Iyengar, N. M., Dang, C. T., & Jones, L. W. (2018). Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. *J Clin Oncol*,

- 36(22), 2297-2305. doi:10.1200/jco.2017.77.5809
71. Romanoff, A., **Zabor, E. C.**, Petruolo, O., Stempel, M., El-Tamer, M., Morrow, M., & Barrio, A. V. (2018). Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? *Cancer*, 124(22), 4314-4321. doi:10.1002/cncr.31757
  72. Romanoff, A., **Zabor, E. C.**, Stempel, M., Sacchini, V., Pusic, A., & Morrow, M. (2018). A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. *Ann Surg Oncol*, 25(10), 2909-2916. doi:10.1245/s10434-018-6585-4
  73. Moo, T. A., Edelweiss, M., Hajiyeve, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A., & Morrow, M. (2018). Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, 25(6), 1488-1494. doi:10.1245/s10434-018-6429-2
  74. Lee, B. H., **Zabor, E. C.**, Tennenbaum, D., Furberg, H., Benfante, N., Coleman, J. A., Jaimes, E. A., & Russo, P. (2018). Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*, 36(2), 257-263. doi:10.1007/s00345-017-2139-9
  75. Francis, J. H., Levin, A. M., **Zabor, E. C.**, Gobin, Y. P., & Abramson, D. H. (2018). Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. *PLoS One*, 13(5), e0197081. doi:10.1371/journal.pone.0197081
  76. Cronin, P. A., Romanoff, A., **Zabor, E. C.**, Stempel, M., Eaton, A., Smyth, L. M., Ho, A. Y., Morrow, M., El-Tamer, M., & Gemignani, M. L. (2018). Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. *Ann Surg Oncol*, 25(13), 3858-3866. doi:10.1245/s10434-018-6767-0
  77. Cassidy, M. R., **Zabor, E. C.**, Stempel, M., Mehrara, B., & Gemignani, M. L. (2018). Does response to neo-adjuvant chemotherapy impact breast reconstruction? *Breast J*, 24(4), 567-573. doi:10.1111/tbj.12977
  78. **Zabor, E. C.** (2019). riskclustr: Functions to Study Etiologic Heterogeneity. *Journal of Open Source Software*, 4(35), 1269. doi:10.21105/joss.01269
  79. Walsh, S. M., Brennan, S. B., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Lebron-Zapata, L., & Gemignani, M. L. (2019). Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy? *Ann Surg Oncol*, 26(13), 4246-4253. doi:10.1245/s10434-019-07647-7
  80. Walsh, S. M., **Zabor, E. C.**, Stempel, M., Morrow, M., & Gemignani, M. L. (2019). Does race predict survival for women with invasive breast cancer? *Cancer*, 125(18), 3139-3146. doi:10.1002/cncr.32296
  81. Van Zee, K. J., **Zabor, E. C.**, Di Donato, R., Harmon, B., Fox, J., Morrow, M., Cody, H. S., 3rd, & Fineberg, S. A. (2019). Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. *Ann Surg Oncol*, 26(10), 3282-3288. doi:10.1245/s10434-019-07537-y
  82. Spanheimer, P. M., Murray, M. P., **Zabor, E. C.**, Stempel, M., Morrow, M., Van Zee, K. J., & Barrio, A. V. (2019). Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. *Ann Surg Oncol*, 26(7), 2136-2143. doi:10.1245/s10434-019-07210-4
  83. Pilewskie, M., **Zabor, E. C.**, Gilbert, E., Stempel, M., Petruolo, O., Mangino, D., Robson, M., & Jochelson, M. S. (2019). Differences between screen-detected and interval breast cancers among BRCA mutation carriers. *Breast Cancer Res Treat*, 175(1), 141-148. doi:10.1007/s10549-018-05123-6
  84. Pietzak, E. J., **Zabor, E. C.**, Bagrodia, A., Armenia, J., Hu, W., Zehir, A., Funt, S., Audenet, F., Barron, D., Maamouri, N., Li, Q., Teo, M. Y., Arcila, M. E., Berger, M. F., Schultz, N., Dalbagni, G., Herr, H. W., Bajorin, D. F., Rosenberg, J. E., Al-Ahmadie, H., Bochner, B. H., Solit, D. B., & Iyer, G. (2019). Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. *Eur Urol*, 75(2), 231-239. doi:10.1016/j.eururo.2018.09.002
  85. Moo, T. A., Jochelson, M. S., **Zabor, E. C.**, Stempel, M., Raiss, M., Mamtani, A., Tadros, A. B., El-Tamer, M., & Morrow, M. (2019). Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI. *Ann Surg Oncol*, 26(13), 4238-4243. doi:10.1245/s10434-019-07867-x
  86. Miller, M. E., Muhsen, S., **Zabor, E. C.**, Flynn, J., Olcese, C., Giri, D., Van Zee, K. J., & Pilewskie, M. (2019). Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. *Ann Surg Oncol*, 26(13), 4317-4325. doi:10.1245/s10434-019-07796-9
  87. Mamtani, A., **Zabor, E. C.**, Rosenberger, L. H., Stempel, M., Gemignani, M. L., & Morrow, M. (2019). Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-



- ASTRO Margin Guidelines? *Ann Surg Oncol*, 26(12), 3856-3862. doi:10.1245/s10434-019-07751-8
88. Mamtani, A., Nakhlis, F., Downs-Canner, S., **Zabor, E. C.**, Morrow, M., King, T. A., & Van Zee, K. J. (2019). Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. *Ann Surg Oncol*, 26(13), 4264-4271. doi:10.1245/s10434-019-07693-1
  89. Mamtani, A., **Zabor, E. C.**, Stempel, M., & Morrow, M. (2019). Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. *Ann Surg Oncol*, 26(10), 3269-3274. doi:10.1245/s10434-019-07536-z
  90. Grabenstetter, A., Moo, T. A., Hajiyevea, S., Schüffler, P. J., Khattar, P., Friedlander, M. A., McCormack, M. A., Raiss, M., **Zabor, E. C.**, Barrio, A., Morrow, M., & Edelweiss, M. (2019). Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma. *Am J Surg Pathol*, 43(10), 1377-1383. doi:10.1097/pas.0000000000001311
  91. Flanagan, M. R., **Zabor, E. C.**, Romanoff, A., Fuzesi, S., Stempel, M., Mehrara, B. J., Morrow, M., Pusic, A. L., & Gemignani, M. L. (2019). A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. *Ann Surg Oncol*, 26(10), 3133-3140. doi:10.1245/s10434-019-07548-9
  92. Flanagan, M. R., **Zabor, E. C.**, Stempel, M., Mangino, D. A., Morrow, M., & Pilewskie, M. L. (2019). Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. *Ann Surg Oncol*, 26(7), 2127-2135. doi:10.1245/s10434-019-07236-8
  93. Engel, L. S., **Zabor, E. C.**, Satagopan, J., Widell, A., Rothman, N., O'Brien, T. R., Zhang, M., Van Den Eeden, S. K., & Grimsrud, T. K. (2019). Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Int J Cancer*, 145(9), 2360-2371. doi:10.1002/ijc.32175
  94. Downs-Canner, S., **Zabor, E. C.**, Wind, T., Cobovic, A., McCormick, B., Morrow, M., & Heerdt, A. (2019). Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose? *Ann Surg Oncol*, 26(4), 969-975. doi:10.1245/s10434-018-07151-4
  95. Casuscelli, J., Becerra, M. F., Manley, B. J., **Zabor, E. C.**, Reznik, E., Redzematovic, A., Arcila, M. E., Tennenbaum, D. M., Ghanaat, M., Kashan, M., Stief, C. G., Carlo, M., Voss, M. H., Feldman, D. R., Motzer, R. J., Chen, Y., Reuter, V. E., Coleman, J. A., Russo, P., Hsieh, J. J., & Hakimi, A. A. (2019). Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. *Eur Urol Focus*, 5(4), 642-649. doi:10.1016/j.euf.2017.09.008
  96. Benefield, H. C., **Zabor, E. C.**, Shan, Y., Allott, E. H., Begg, C. B., & Troester, M. A. (2019). Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev*, 28(11), 1784-1791. doi:10.1158/1055-9965.Epi-19-0365
  97. Baker, J. L., Muhsen, S., **Zabor, E. C.**, Stempel, M., & Gemignani, M. L. (2019). Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? *Ann Surg Oncol*, 26(2), 336-342. doi:10.1245/s10434-018-7004-6
  98. Walsh, S. M., **Zabor, E. C.**, Flynn, J., Stempel, M., Morrow, M., & Gemignani, M. L. (2020). Breast cancer in young black women. *Br J Surg*, 107(6), 677-686. doi:10.1002/bjs.11401
  99. Valero, M. G., Moo, T. A., Muhsen, S., **Zabor, E. C.**, Stempel, M., Pusic, A., Gemignani, M. L., Morrow, M., & Sacchini, V. (2020). Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. *Br J Surg*, 107(10), 1307-1312. doi:10.1002/bjs.11616
  100. Valero, M. G., Muhsen, S., Moo, T. A., **Zabor, E. C.**, Stempel, M., Pusic, A., Gemignani, M. L., Morrow, M., & Sacchini, V. S. (2020). Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. *Ann Surg Oncol*, 27(2), 344-351. doi:10.1245/s10434-019-07948-x
  101. Valero, M. G., **Zabor, E. C.**, Park, A., Gilbert, E., Newman, A., King, T. A., & Pilewskie, M. L. (2020). The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. *Ann Surg Oncol*, 27(3), 736-740. doi:10.1245/s10434-019-07814-w
  102. Tadros, A. B., Moo, T. A., **Zabor, E. C.**, Gillespie, E. F., Khan, A., McCormick, B., Cahlon, O., Powell, S. N., Allen, R., Jr., Morrow, M., & Braunstein, L. Z. (2020). Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. *Pract Radiat Oncol*, 10(5), e357-e362. doi:10.1016/j.prro.2020.01.003
  103. Tadros, A. B., Moo, T. A., Stempel, M., **Zabor, E. C.**, Khan, A. J., & Morrow, M. (2020). Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. *Breast Cancer Res Treat*, 180(1), 197-205. doi:10.1007/s10549-019-05520-5

104. Raghunathan, N. J., **Zabor, E. C.**, Anderson, N., Oeffinger, K., Tonorezos, E. S., & Korenstein, D. (2020). Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool. *J Cancer Surviv*, 14(4), 417-423. doi:10.1007/s11764-020-00860-4
105. Niehoff, N. M., **Zabor, E. C.**, Satagopan, J., Widell, A., O'Brien, T. R., Zhang, M., Rothman, N., Grimsrud, T. K., Van Den Eeden, S. K., & Engel, L. S. (2020). Prediagnostic serum polychlorinated biphenyl concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. *Environ Res*, 187, 109690. doi:10.1016/j.envres.2020.109690
106. Minami, C. A., **Zabor, E. C.**, Gilbert, E., Newman, A., Park, A., Jochelson, M. S., King, T. A., & Pilewskie, M. L. (2020). Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? *Ann Surg Oncol*, 27(6), 1844-1851. doi:10.1245/s10434-019-08126-9
107. Iyer, G., Tully, C. M., **Zabor, E. C.**, Bochner, B. H., Dalbagni, G., Herr, H. W., Donat, S. M., Russo, P., Ostrovnaya, I., Regazzi, A. M., Milowsky, M. I., Rosenberg, J. E., & Bajorin, D. F. (2020). Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. *Clin Genitourin Cancer*, 18(5), 387-394. doi:10.1016/j.clgc.2020.02.014
108. Crown, A., Muhsen, S., **Zabor, E. C.**, Sevilimedu, V., Kelvin, J., Goldfarb, S. B., & Gemignani, M. L. (2020). Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer? *Ann Surg Oncol*, 27(12), 4740-4749. doi:10.1245/s10434-020-08883-y
109. Christian, N., **Zabor, E. C.**, Cassidy, M., Flynn, J., Morrow, M., & Gemignani, M. L. (2020). Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. *Ann Surg Oncol*, 27(3), 743-749. doi:10.1245/s10434-019-08038-8
110. Brierley, C. K., **Zabor, E. C.**, Komrokji, R. S., DeZern, A. E., Roboz, G. J., Brunner, A. M., Stone, R. M., Sekeres, M. A., & Steensma, D. P. (2020). Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. *Cancer*, 126(21), 4735-4743. doi:10.1002/cncr.33105
111. Bilani, N., **Zabor, E. C.**, Elson, L., Elimimian, E. B., & Nahleh, Z. (2020). Breast Cancer in the United States: A Cross-Sectional Overview. *J Cancer Epidemiol*, 2020, 6387378. doi:10.1155/2020/6387378
112. **Zabor, E. C.**, Radivoyevitch, T., Singh, A. D., Kilic, E., de Klein, J., Kalirai, H., & Coupland, S. E. (2021). Conditional Survival in Uveal Melanoma. *Ophthalmol Retina*, 5(6), 536-542. doi:10.1016/j.oret.2020.09.015
113. **Zabor, E. C.**, Seshan, V. E., Wang, S., & Begg, C. B. (2021). Validity of a method for identifying disease subtypes that are etiologically heterogeneous. *Stat Methods Med Res*, 30(9), 2045-2056. doi:10.1177/09622802211032704
114. Tadros, A. B., Sevilimedu, V., Giri, D. D., **Zabor, E. C.**, Morrow, M., & Plitas, G. (2021). Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype. *Ann Surg Oncol*, 28(8), 4245-4253. doi:10.1245/s10434-020-09430-5
115. Singh, A. D., **Zabor, E. C.**, & Radivoyevitch, T. (2021). Estimating Cured Fractions of Uveal Melanoma. *JAMA Ophthalmol*, 139(2), 174-181. doi:10.1001/jamaophthalmol.2020.5720
116. Raval, V., Luo, S., **Zabor, E. C.**, & Singh, A. D. (2021). Small Choroidal Melanoma: Correlation of Growth Rate with Pathology. *Ocul Oncol Pathol*, 7(6), 401-410. doi:10.1159/000517203
117. Radivoyevitch, T., **Zabor, E. C.**, & Singh, A. D. (2021). Uveal melanoma: Long-term survival. *PLoS One*, 16(5), e0250939. doi:10.1371/journal.pone.0250939
118. Pawloski, K. R., Tadros, A. B., Sevilimedu, V., Newman, A., Gentile, L., **Zabor, E. C.**, Morrow, M., Van Zee, K. J., & Kirstein, L. J. (2021). Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. *Breast Cancer Res Treat*, 186(3), 617-624. doi:10.1007/s10549-021-06129-3
119. Palacios, D. A., **Zabor, E. C.**, Munoz-Lopez, C., Roversi, G., Mahmood, F., Abramczyk, E., Kelly, M., Wilson, B., Abouassaly, R., & Campbell, S. C. (2021). Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? *Eur Urol*, 79(6), 774-780. doi:10.1016/j.eururo.2021.02.035
120. Luo, S., Raval, V., **Zabor, E. C.**, & Singh, A. D. (2021). Small Choroidal Melanoma: Correlation between Clinical Characteristics and Metastatic Potential. *Ocul Oncol Pathol*, 7(6), 437-446. doi:10.1159/000519672
121. Elimimian, E. B., Elson, L., Li, H., Liang, H., Bilani, N., **Zabor, E. C.**, Statler, A., & Nahleh, Z. (2021). Male Breast Cancer: A Comparative Analysis from the National Cancer Database. *World J Mens Health*,

- 39(3), 506-515. doi:10.5534/wjmh.200164
122. **Zabor, E. C.**, Raval, V., Luo, S., Pelayes, D. E., & Singh, A. D. (2022). A Prediction Model to Discriminate Small Choroidal Melanoma from Choroidal Nevus. *Ocul Oncol Pathol*, 8(1), 71-78. doi:10.1159/000521541
  123. **Zabor, E. C.**, Kane, M. J., Roychoudhury, S., Nie, L., & Hobbs, B. P. (2022). Bayesian basket trial design with false-discovery rate control. *Clin Trials*, 19(3), 297-306. doi:10.1177/17407745211073624
  124. **Zabor, E. C.**, Kaizer, A. M., Garrett-Mayer, E., & Hobbs, B. P. (2022). Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. *JCO Precis Oncol*, 6, e2100390. doi:10.1200/po.21.00390
  125. **Zabor, E. C.**, Kaizer, A. M., Pennell, N. A., & Hobbs, B. P. (2022). Optimal predictive probability designs for randomized biomarker-guided oncology trials. *Frontiers in Oncology*, 12. doi:10.3389/fonc.2022.955056
  126. Sittenfeld, S., **Zabor, E. C.**, Hamilton, S. N., Kuerer, H. M., El-Tamer, M., Naoum, G. E., Truong, P. T., Nichol, A., Smith, B. D., Woodward, W. A., Moo, T. A., Powell, S. N., Shah, C. S., Taghian, A. G., Abu-Gheida, I., & Tendulkar, R. D. (2022). A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer. *Cancer*, 10.1002/cncr.34352. Advance online publication. <https://doi.org/10.1002/cncr.34352>
  127. Singh, A. D., Raval, V., Wrenn, J., & **Zabor, E. C.** (2022). Small Choroidal Melanoma: Outcomes After Surveillance Versus Immediate Treatment. *Am J Ophthalmol*, 241, 47-56. doi:10.1016/j.ajo.2022.03.024
  128. Salz, T., **Zabor, E. C.**, Brown, P. N., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., Steingart, R., Hjalgrim, H., Specht, L., Vickers, A. J., Oeffinger, K. C., & Johansen, C. (2022). Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors. *Acta Oncol*, 61(9), 1064-1068. doi:10.1080/0284186x.2022.2107402
  129. Lemmon, C. A., **Zabor, E. C.**, & Pennell, N. A. (2022). Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. *Oncologist*, 27(5), 407-413. doi:10.1093/oncolo/oyac021
  130. Kaizer, A., **Zabor, E.**, Nie, L., & Hobbs, B. (2022). Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. *PLoS One*, 17(8), e0272367. doi:10.1371/journal.pone.0272367
  131. Javidi, H., Mariam, A., Khademi, G., **Zabor, E. C.**, Zhao, R., Radivoyevitch, T., & Rotroff, D. M. (2022). Identification of robust deep neural network models of longitudinal clinical measurements. *NPJ Digit Med*, 5(1), 106. doi:10.1038/s41746-022-00651-4
  132. Eaton, A. A. \*, & **Zabor, E. C.** \* (2022). Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules. *Stat Med*, 41(9), 1599-1612. doi:10.1002/sim.9312  
\*equally contributing authors
  133. **Zabor, E. C.**, Hobbs, B. P., Kane, M. J. (2023). ppseq: An R Package for Sequential Predictive Probability Monitoring. *The R Journal*, 14(4), 280-290. Doi: 10.32614/RJ-2023-017
  134. Yeşiltaş, Y. S., **Zabor, E. C.**, Wrenn, J., Oakey, Z., & Singh, A. D. (2023). Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols. *Cancers (Basel)*, 15(20). doi:10.3390/cancers15205025
  135. D'Angelica, M. I., Ellis, R. J., Liu, J. B., Brajcich, B. C., Gönen, M., Thompson, V. M., Cohen, M. E., Seo, S. K., **Zabor, E. C.**, Babicky, M. L., Bentrem, D. J., Behrman, S. W., Bertens, K. A., Celinski, S. A., Chan, C. H. F., Dillhoff, M., Dixon, M. E. B., Fernandez-Del Castillo, C., Gholami, S., House, M. G., Karanickolas, P. J., Lavu, H., Maithel, S. K., McAuliffe, J. C., Ott, M. J., Reames, B. N., Sanford, D. E., Sarpel, U., Scaife, C. L., Serrano, P. E., Smith, T., Snyder, R. A., Talamonti, M. S., Weber, S. M., Yopp, A. C., Pitt, H. A., & Ko, C. Y. (2023). Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. *Jama*, 329(18), 1579-1588. doi:10.1001/jama.2023.5728
  136. Yeşiltaş, Y. S., Zhou, M., **Zabor, E. C.**, Oakey, Z., Singh, N., Sedaghat, A., Yeane, G., & Singh, A. D. (2024). Iris freckle: a distinct entity. *Br J Ophthalmol*. doi:10.1136/bjo-2023-325009
  137. Toro, P., Bakhshwin, A., Zein-Sabatto, B., Khaitan, N., Duckworth, L., Bennett, A., Elsoukary, S. S., Zhang, X., Govande, S., **Zabor, E. C.**, Liska, D., Balagamwala, E., & Allende, D. S. (2024). Computational Pathology-Enabled Residual Tumor Estimation is a Prognostic Factor for Overall Survival in Anal Squamous Cell Carcinoma. *Mod Pathol*, 100692. doi:10.1016/j.modpat.2024.100692

138. Singh, A., Melendez-Moreno, A., Krohn, J., & **Zabor, E. C.** (2024). Predictive model for iris melanoma. *Br J Ophthalmol*, 108(11), 1598-1604. doi:10.1136/bjo-2023-324558
139. Mariam, A., Javidi, H., **Zabor, E. C.**, Zhao, R., Radivoyevitch, T., & Rotroff, D. M. (2024). Unsupervised clustering of longitudinal clinical measurements in electronic health records. *PLOS Digit Health*, 3(10), e0000628. doi:10.1371/journal.pdig.0000628
140. Kim, M. K., Roupheal, C., Wehbe, S., Yoon, J. Y., Wisnivesky, J., McMichael, J., Welch, N., Dasarathy, S., & **Zabor, E. C.** (2024). Using the Electronic Health Record to Develop a Gastric Cancer Risk Prediction Model. *Gastro Hep Adv*, 3(7), 910-916. doi:10.1016/j.gastha.2024.07.001
141. Gutgarts, V., Gerardine, S., Shingarev, R. A., Knezevic, A., **Zabor, E. C.**, Latcha, S., Joy, M. S., Aleksunes, L. M., & Jaimes, E. A. (2024). Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Coprescribed Serotonin Receptor Antagonists: A Retrospective Analysis. *Kidney360*, 5(8), 1094-1100. doi:10.34067/kid.0000000000000464

### **Invited, Non-Peer Reviewed Articles**

1. Campbell, P. T., Rebbeck, T. R., Nishihara, R., Beck, A. H., Begg, C. B., Bogdanov, A. A., Cao, Y., Coleman, H. G., Freeman, G. J., Heng, Y. J., Huttenhower, C., Irizarry, R. A., Kip, N. S., Michor, F., Nevo, D., Peters, U., Phipps, A. I., Poole, E. M., Qian, Z. R., Quackenbush, J., Robins, H., Rogan, P. K., Slattery, M. L., Smith-Warner, S. A., Song, M., VanderWeele, T. J., Xia, D., **Zabor, E. C.**, Zhang, X., Wang, M., & Ogino, S. (2017). Proceedings of the third international molecular pathological epidemiology (MPE) meeting. *Cancer Causes Control*, 28(2), 167-176. doi:10.1007/s10552-016-0845-z
2. **Zabor, E. C.** (2018). ASO Author Reflections: Careful Development and Thoughtful Interpretation are Needed when Developing Online Prognostic Tools. *Ann Surg Oncol*, 25(Suppl 3), 916-917. doi:10.1245/s10434-018-6987-3
3. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *J Urol*, 201(3), 595-604. doi:10.1097/ju.0000000000000001
4. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for Reporting of Statistics for Clinical Research in Urology. *Eur Urol*, 75(3), 358-367. doi:10.1016/j.eururo.2018.12.014
5. Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., Hollenbeck, B., Qin, R., Zahnd, W., **Zabor, E. C.**, Kattan, M. W., & Vickers, A. J. (2019). Guidelines for reporting of statistics for clinical research in urology. *BJU Int*, 123(3), 401-410. doi:10.1111/bju.14640
6. **Zabor, E. C.**, Kaizer, A. M., & Hobbs, B. P. (2020). Randomized Controlled Trials. *Chest*, 158(1s), S79-S87. doi:10.1016/j.chest.2020.03.013
7. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *BJU Int*, 126(1), 14-25. doi:10.1111/bju.15102
8. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Eur Urol*, 78(1), 97-109. doi:10.1016/j.eururo.2020.04.048
9. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *Urology*, 142, 1-13. doi:10.1016/j.urology.2020.05.002
10. Vickers, A. J., Assel, M. J., Sjoberg, D. D., Qin, R., Zhao, Z., Koyama, T., Botchway, A., Wang, X., Huo, D., Kattan, M., **Zabor, E. C.**, & Harrell, F. (2020). Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. *J Urol*, 204(1), 121-133. doi:10.1097/ju.0000000000001096
11. **Zabor, E. C.**, Reddy, C. A., Tendulkar, R. D., & Patil, S. (2022). Logistic Regression in Clinical Studies. *Int J Radiat Oncol Biol Phys*, 112(2), 271-277. doi:10.1016/j.ijrobp.2021.08.007
12. Hobbs, B. P., Pestana, R. C., **Zabor, E. C.**, Kaizer, A. M., & Hong, D. S. (2022). Basket Trials: Review of Current Practice and Innovations for Future Trials. *J Clin Oncol*, Jco2102285. doi:10.1200/jco.21.02285
13. **Zabor, E. C.**, & Assel, M. (2023). On the Need for Landmark Analysis or Time-dependent Covariates. *J Urol*, 209(6), 1060-1062. doi:10.1097/ju.0000000000003459
14. Vickers, A. J., Assel, M., Dunn, R. L., **Zabor, E. C.**, Kattan, M. W., van Smeden, M., & Dahly, D. (2023).

Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality. *Eur Urol*, 84(2), 147-151. doi:10.1016/j.eururo.2023.04.027

15. Vickers, A. J., Assel, M., Dunn, R. L., **Zabor, E. C.**, Kattan, M. W., van Smeden, M., & Dahly, D. (2023). Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality. *J Urol*, 210(1), 10-14. doi:10.1097/ju.0000000000003479
16. Vickers, A. J., Assel, M., Dunn, R. L., **Zabor, E. C.**, Kattan, M. W., van Smeden, M., & Dahly, D. (2023). Guidelines for reporting observational research in urology: the importance of clear reference to causality. *BJU Int*, 132(1), 4-8. doi:10.1111/bju.16028
17. Vickers, A. J., Assel, M., Dunn, R. L., **Zabor, E. C.**, Kattan, M. W., van Smeden, M., & Dahly, D. (2023). Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality. *Urology*, 177, 1-5. doi:10.1016/j.urology.2023.04.007

#### **Media Appearances & Coverage / Podcasts**

1. **Zabor, E. C.** Presenter. "Phase III POSEIDON Clinical Trial Results." JCO Article Insights. February 27, 2023. <https://sites.libsyn.com/58526/JCO/jco-article-insights-phase-iii-poseidon-clinical-trial-results>
2. **Zabor, E. C.** Presenter. "Use of Independently-Assessed vs Investigator-Assessed DFS in the APACT Trial." JCO Article Insights. May 15, 2023. <https://sites.libsyn.com/58526/JCO/jco-article-insights-use-of-independently-assessed-vs-investigator-assessed-dfs-in-the-apact-trial>
3. **Zabor, E. C.** Podcast Presenter. "Two New Prediction Models for Risk of Venous Thromboembolism in Cancer Patients." JCO Article Insights. June 26, 2023. <https://jcopodcast.libsyn.com/jco-article-insights-two-new-prediction-models-for-risk-of-venous-thromboembolism-in-cancer-patients>
4. **Zabor, E. C.** Podcast Presenter. "Introducing The Childhood Cancer Data Initiative." JCO Article Insights. August 28, 2023. <https://jcopodcast.libsyn.com/jco-article-insights-introducing-the-childhood-cancer-data-initiative>

#### **Software / Application Development**

1. **Zabor, E. C.** and Gönen, M. (2018). condSurv: R package for conditional survival estimates and plots. R package version 1.0.0. <https://github.com/zabore/condSurv>.
2. **Zabor, E. C.** (2022). riskclustr: Functions to Study Etiologic Heterogeneity. R package version 0.4.0. <https://CRAN.R-project.org/package=riskclustr>
3. Sjöberg, D. D., Hannum, M., Whiting, K., & **Zabor, E. C.** (2020). gtsummary: Presentation-Ready Data Summary and Analytic Result Tables. R package version 1.3.4. <https://CRAN.R-project.org/package=gtsummary>.
4. **Zabor, E. C.**, Hobbs, B. P., Kane, M. J. (2023). ppseq: Design Clinical Trials using Sequential Predictive Probability Monitoring. R package version 0.2.2. <https://CRAN.R-project.org/package=ppseq>.

#### **Letters**

1. Moskowitz, C. S., **Zabor, E. C.**, & Jochelson, M. (2013). Response to the "letter to the editor" by Dr. Thomas Filleron. *Breast J*, 19(2), 227. doi:10.1111/tbj.12094
2. Teo, M. Y., Bambury, R. M., **Zabor, E. C.**, Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., Ostrovskaya, I., Hyman, D. M., Bochner, B. H., Arcila, M. E., Solit, D. B., Berger, M. F., Bajorin, D. F., Bellmunt, J., Iyer, G., & Rosenberg, J. E. (2018). Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.". *Urol Oncol*, 36(7), 345-346. doi:10.1016/j.urolonc.2018.05.011
3. Begg, C. B., Seshan, V. E., & **Zabor, E. C.** (2018). RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY". *Am J Epidemiol*, 187(5), 1129-1130. doi:10.1093/aje/kwy032
4. Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., **Zabor, E. C.**, Barrio, A. V., & Morrow, M. (2020). Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? *Ann Surg Oncol*, 27(Suppl 3), 966. doi:10.1245/s10434-020-08273-4
5. **Zabor, E. C.** (2021). Comment on "Age Conditional Probability of Ocular and Ocular Adnexal Malignancies". *Ocul Oncol Pathol*, 7(1), 74-75. doi:10.1159/000512031

## **COMMUNITY SERVICE / VOLUNTEER CONTRIBUTIONS**

1. Grinnell College Alumni Association Regional Volunteer, 2020-present
2. Moms Demand Action Data Team Volunteer, 2023-present
3. Northeast Ohio Science and Engineering Fair, Special Awards Judge, 2024